Innovative Developments in Therapeutic Antibody Discovery
Adimab, LLC, recognized as a leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, has made significant strides in expanding its therapeutic product portfolio. Recently, the company announced that five of its therapeutic products, containing molecules either discovered or optimized by Adimab, have gained approval for commercial sale. Notably, the first of these programs was Innovent’s TYVYT, known scientifically as sintilimab injection. This product is currently being marketed in China for a range of cancer treatments.
Expanding Portfolio of Approved Products
Among other notable commercial offerings that feature Adimab-discovered molecules are:
- Innovent’s SINTBILO (tafolecimab injection), related to a PCSK9 program approved in China for treating primary hypercholesterolemia and mixed dyslipidemia.
- IASO Bio’s FUCASO (equecabtagene autoleucel), a BCMA CAR-T program that has received approval in China for treating multiple myeloma.
- Invivyd’s PEMGARDA (pemivibart), a monoclonal antibody aimed at fighting SARS-CoV-2, which is approved for emergency use in the United States.
- Checkpoint Therapeutics’ UNLOXCYT (cosibelimab), which was granted BLA approval for use in multiple myeloma.
Ongoing Clinical Trials and Future Prospects
In addition, Adimab currently has 11 programs actively undergoing Phase II or Phase III clinical trials, enhancing the total count of clinical programs initiated by partners to an impressive 78. Ryan McGovern, Adimab’s Chief Financial Officer, emphasized the commitment of the company to assist in bringing innovative therapies to market efficiently.
Strategic Developments for Growth
In a strategic move to capitalize on its successes, Adimab is restructuring its business model by establishing a separate entity, the Adimab Royalty Company (ARC), to manage royalty rights from more advanced assets. This initiative is expected to attract investors seeking to engage with a growing portfolio of diversified royalty-bearing assets.
Commitment to Quality and Innovation
Philip T. Chase, the Chief Executive Officer of Adimab, shared insights into the core values guiding the firm. He highlighted the company’s relentless dedication to maintaining high-quality execution for partners while avoiding distractions associated with internal product development pipelines. Adimab’s commitment extends to ongoing investments in enhancing its technology platform, ensuring operational discipline, and fostering a talented workforce.
A Broad Spectrum of Collaborative Partnerships
Adimab has established over 115 commercial licenses, enabling partners to undertake clinical developments. In 2024, the firm notably saw 11 partners exercise their commercial options, including prominent names like BMS, NextPoint, and Regeneron.
Advancements in Antibody Technologies
The company excels in various advanced technologies, notably in Antibody Discovery, where it utilizes a proprietary yeast-based technology to develop therapeutic antibodies in both IgG and VHH formats. This ensures a profound specificity applicable across diverse therapeutic modalities.
Continuous Engineering Enhancements
Adimab has honed its engineering capabilities through extensive optimization efforts. Its process begins by selecting lead antibodies and enhancing their properties, allowing for the introduction of external antibodies to rectify any undesirable characteristics.
A Deep Look into Multispecifics and T Cell Engagers
With a wealth of knowledge in multispecific antibodies, Adimab can create product designs characterized by superior developability. Moreover, the company has developed a distinctive suite of CD3 and CD28 antibodies which facilitate the creation of both bi- and multi-specific T cell engagers, a program that has attracted over 25 partnerships.
Complex Targets and Proprietary Workflows
Adimab’s proprietary workflows also cater to complex targets, enabling successful antibody discovery for membrane proteins and other challenging classes without reliance on antigen mimetics, thereby broadening the range of therapeutic targets.
About Adimab
Adimab stands as a preeminent provider of therapeutic antibody discovery and engineering technologies. With a focus solely on partnership, the company has collaborated with more than 130 pharmaceutical and biotech companies since its inception in 2009, contributing to an extensive portfolio of therapeutic programs and approved products. The Adimab platform is employed by renowned leaders in the pharmaceutical sector, showcasing its invaluable role in advancing therapeutic antibody creation.
Frequently Asked Questions
What is Adimab's main focus?
Adimab primarily concentrates on discovering and engineering therapeutic antibodies, emphasizing collaborations rather than developing its internal product pipeline.
What recent approvals has Adimab achieved?
Recently, five products containing molecules discovered by Adimab received commercial approval, including Innovent’s TYVYT for cancer treatment.
How many clinical programs are associated with Adimab?
Adimab is currently involved with 78 clinical programs initiated by its partners.
What innovative technology does Adimab use?
Adimab employs a yeast-based technology for antibody discovery, allowing for precise therapeutic antibody generation.
Who are Adimab's partners?
The company collaborates with over 130 pharmaceutical and biotech companies, including major firms like Regeneron and Bristol Myers Squibb.
